Emyria has opened a new facility – The Empax Centre – and expanded its clinical service capacity to deliver and develop new treatments for mental health including MDMA-assisted therapy (MDMA-AT) for PTSD.
Led by some of Australia’s first authorised MDMA-AT prescribers, Emyria said the Empax Centre is aiming to achieve operational profitability by H2 2024 with the potential for national and global scalability via further site expansion.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
